Art. 3 Directive (EU) 2001/83

In forcesince 30 Dec 2008cited 35×

This Directive shall not apply to:

1.

Any medicinal product prepared in a pharmacy in accordance with a medical prescription for an individual patient (commonly known as the magistral formula).

2.

Any medicinal product which is prepared in a pharmacy in accordance with the prescriptions of a pharmacopoeia and is intended to be supplied directly to the patients served by the pharmacy in question (commonly known as the officinal formula).

3.

Medicinal products intended for research and development trials, but without prejudice to the provisions of Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use [OJ L 121, 1.5.2001, p. 34.].

4.

Intermediate products intended for further processing by an authorized manufacturer.

5.

Any radionuclides in the form of sealed sources.

6.

Whole blood, plasma or blood cells of human origin, except for plasma which is prepared by a method involving an industrial process.

7.

Any advanced therapy medicinal product, as defined in Regulation (EC) No 1394/2007, which is prepared on a non-routine basis according to specific quality standards, and used within the same Member State in a hospital under the exclusive professional responsibility of a medical practitioner, in order to comply with an individual medical prescription for a custom-made product for an individual patient.

Manufacturing of these products shall be authorised by the competent authority of the Member State. Member States shall ensure that national traceability and pharmacovigilance requirements as well as the specific quality standards referred to in this paragraph are equivalent to those provided for at Community level in respect of advanced therapy medicinal products for which authorisation is required pursuant to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency [OJ L 136, 30.4.2004, p. 1. Regulation as amended by Regulation (EC) No 1901/2006 (OJ L 378, 27.12.2006, p. 1).].

The 10 that are cited most themselves, of 35.

  • Judgment of the Court (Third Chamber) of 16 July 2015. Abcur AB v Apoteket Farmaci AB and Apoteket AB.Decision

    It follows therefrom that, in order to fall within the scope of Directive 2001/83, the product in question, firstly, must satisfy the conditions laid down in Article 2(1) of that directive and, secondly, must not fall within one of the …

    16 Jul 2015 · 62013CJ0544

  • Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 Novembe…Lawamends

  • Judgment of the Court (Fourth Chamber), 11 April 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision

    Article 3 of that directive provides: ‘This Directive shall not apply to: Any medicinal product prepared in a pharmacy in accordance with a medical prescription for an individual patient (commonly known as the magistral formula). Any …

    11 Apr 2013 · 62011CJ0535

  • Judgment of the Court (First Chamber) of 26 October 2016. Hecht-Pharma GmbH v Hohenzollern Apotheke, Winfried Ertelt.Decision

    Although the questions referred for a preliminary ruling relate exclusively to the interpretation of Article 3 of Directive 2001/83, it is appropriate to consider that, by those questions, the referring court is asking, in essence, whether …

    26 Oct 2016 · 62015CJ0276

  • Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decision

    In those circumstances, the Consiglio di Stato (Council of State) decided to stay the proceedings and to refer the following questions to the Court of Justice for a preliminary ruling: Do the provisions of Directive 2001/83 and in …

    21 Nov 2018 · 62017CJ0029

  • Judgment of the Court (First Chamber), 13 March 2014. Octapharma France SAS v Agence nationale de sécurité du médicament et des produits de Decision

    Article 3 of Directive 2001/83, as amended by Directive 2004/27, provides: ‘This Directive shall not apply to: … Whole blood, plasma or blood cells of human origin, except for plasma which is prepared by a method involving an …

    13 Mar 2014 · 62012CJ0512

  • Opinion of Advocate General Szpunar delivered on 3 March 2015. Abcur AB v Apoteket Farmaci AB and Apoteket AB.Decision

    While the question explicitly refers to Article 3 of Directive 2001/83, the referring court appears to be unclear about the relationship between Articles 2 and 3. It should therefore first be clarified whether the conditions of Article 2 …

    3 Mar 2015 · 62013CC0544

  • Raad van State, 01-05-2013, 201201373/1/A3Decision

    … "op kleine schaal" aan die bepalingen is toegevoegd om de uitzondering voor in de apotheek bereide geneesmiddelen die artikel 3 van Richtlijn 2001/83 maakt, meer in overeenstemming te brengen met de terminologie die artikel 40, tweede lid, …

    1 May 2013 · ECLI:NL:RVS:2013:BZ9066

  • Opinion of Advocate General Szpunar delivered on 30 June 2016. Hecht-Pharma GmbH v Hohenzollern Apotheke, Winfried Ertelt.Decision

    Despite the fact that it is not apparent from the text of Directive 2001/83 or from systematic or teleological considerations relating to the interpretation of that directive, [See my Opinion in Joined Cases Abcur (C‑544/13 and …

    30 Jun 2016 · 62015CC0276

  • Judgment of the Court (Grand Chamber) of 22 December 2022. SIA 'EUROAPTIEKA' v Ministru kabinets.Decision

    … de los medicamentos no autorizados, los sujetos a receta médica o los reembolsables, de conformidad con los artículos 87, apartado 1, y 88, apartados 1, letra a), y 3, de la Directiva 2001/83.

    22 Dec 2022 · 62020CJ0530